- Home
- FEMY vs RDI Comparison
FEMY vs RDI Comparison
Compare FEMY & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- RDI
- Stock Information
- Founded
- FEMY 2004
- RDI 1937
- Country
- FEMY United States
- RDI United States
- Employees
- FEMY N/A
- RDI N/A
- Industry
- FEMY Medical/Dental Instruments
- RDI Movies/Entertainment
- Sector
- FEMY Health Care
- RDI Consumer Discretionary
- Exchange
- FEMY Nasdaq
- RDI Nasdaq
- Market Cap
- FEMY 29.9M
- RDI 27.9M
- IPO Year
- FEMY 2021
- RDI N/A
- Fundamental
- Price
- FEMY $0.87
- RDI $1.32
- Analyst Decision
- FEMY Strong Buy
- RDI
- Analyst Count
- FEMY 3
- RDI 0
- Target Price
- FEMY $8.67
- RDI N/A
- AVG Volume (30 Days)
- FEMY 274.9K
- RDI 29.3K
- Earning Date
- FEMY 08-07-2025
- RDI 08-13-2025
- Dividend Yield
- FEMY N/A
- RDI N/A
- EPS Growth
- FEMY N/A
- RDI N/A
- EPS
- FEMY N/A
- RDI N/A
- Revenue
- FEMY $1,699,232.00
- RDI $205,644,000.00
- Revenue This Year
- FEMY $283.83
- RDI $7.47
- Revenue Next Year
- FEMY $161.03
- RDI $13.22
- P/E Ratio
- FEMY N/A
- RDI N/A
- Revenue Growth
- FEMY 61.97
- RDI N/A
- 52 Week Low
- FEMY $0.69
- RDI $1.17
- 52 Week High
- FEMY $1.80
- RDI $1.89
- Technical
- Relative Strength Index (RSI)
- FEMY 47.01
- RDI 53.64
- Support Level
- FEMY $0.91
- RDI $1.27
- Resistance Level
- FEMY $0.99
- RDI $1.36
- Average True Range (ATR)
- FEMY 0.04
- RDI 0.06
- MACD
- FEMY 0.00
- RDI 0.01
- Stochastic Oscillator
- FEMY 22.33
- RDI 90.87
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.